VenatoRx was named one of the “2018 Best Places to Work” in the Greater Philadelphia area by the Philadelphia Business Journal. Founded in 2010, VenatoRx has grown from three founders to over 50 employees who are heavily comprised of entrepreneurial-minded scientists and operators who have had career success in big pharma and start-up environments. Headquartered in Malvern, PA, VenatoRx operates in a 25,000 square foot facility comprised of both laboratory and office space.

President and CEO, Christopher J. Burns, Ph.D., will present attendees with an overview of VenatoRx’s pipeline and its unique operating model of leveraging non-dilutive funding to maximize investor dollars on Monday, 21, 2018 at 8:00am ET in Ballroom V at the Grand Hyatt New York.

The awards program recognizes entrepreneurs who are excelling in areas such as innovation, financial performance and personal commitment to their businesses and communities. Drs. Burns, Xerri and Pevear were selected as finalists by a panel of independent judges. Award winners will be announced at a special gala event on June 14, 2018 at the Kimmel Center for the Performing Arts.

Fourteen poster presentations, including four oral sessions, will feature VenatoRx's lead clinical antibacterial candidate, cefepime/VNRX-5133, at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Madrid, Spain. In addition, VenatoRx’s President and CEO, Christopher J. Burns, Ph.D., will present a brief overview about the Company’s R&D pipeline during Pipeline Corner on April 23, 2013 beginning at 12:30pm CET in Hall Y.

President and CEO, Christopher J. Burns, Ph.D., will present the Company's lead clinical antibacterial candidate, VNRX-5133, during the First-Time Disclosure of Clinical Candidates Symposium at the American Chemical Society (ACS) National Meeting on Wednesday, March 21, 2018 at 3:15pm CT. The oral presentation is entitled, “Discovery of VNRX-5133: A broad-spectrum serine- and metallo-beta-lactamase inhibitor (BLI) for carbapenem-resistant bacterial infections (“superbugs”).”

The funding will support discovery and preclinical development of a novel, first-in-class antibiotic for biodefense applications. The project derives from the company’s proprietary platform of non-beta-lactam penicillin binding protein inhibitors (PBPis).

The FDA granted VenatoRx's lead antibiotic program, VNRX-5133, an injectable broad-spectrum beta-lactamase inhibitor combined with a marketed beta-lactam antibiotic, both the Qualified Infectious Disease Product (QIDP) and Fast Track designations. The designations were granted for both complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).